Stryker Co. (NYSE:SYK) Stock Holdings Reduced by GTS Securities LLC

GTS Securities LLC cut its position in shares of Stryker Co. (NYSE:SYK - Free Report) by 24.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,400 shares of the medical technology company's stock after selling 776 shares during the quarter. GTS Securities LLC's holdings in Stryker were worth $864,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. Capital & Planning LLC grew its holdings in shares of Stryker by 3.6% during the fourth quarter. Capital & Planning LLC now owns 841 shares of the medical technology company's stock valued at $304,000 after purchasing an additional 29 shares during the last quarter. Brighton Jones LLC boosted its position in Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock valued at $1,643,000 after purchasing an additional 609 shares during the period. RFG Advisory LLC grew its stake in Stryker by 4.4% during the 4th quarter. RFG Advisory LLC now owns 1,316 shares of the medical technology company's stock worth $474,000 after buying an additional 56 shares during the last quarter. Exchange Traded Concepts LLC increased its position in Stryker by 19.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 6,263 shares of the medical technology company's stock worth $2,255,000 after buying an additional 1,002 shares during the period. Finally, Fifth Third Bancorp lifted its stake in Stryker by 1.0% in the fourth quarter. Fifth Third Bancorp now owns 89,407 shares of the medical technology company's stock valued at $32,191,000 after buying an additional 845 shares during the last quarter. Institutional investors own 77.09% of the company's stock.

Analysts Set New Price Targets

SYK has been the topic of several recent research reports. JMP Securities reiterated a "market perform" rating on shares of Stryker in a research report on Monday, May 5th. Wells Fargo & Company boosted their price objective on Stryker from $427.00 to $435.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 29th. Truist Financial raised their target price on Stryker from $390.00 to $400.00 and gave the company a "hold" rating in a research report on Monday, May 5th. Needham & Company LLC reiterated a "buy" rating and set a $442.00 price target on shares of Stryker in a research report on Friday, March 21st. Finally, Royal Bank of Canada increased their price target on Stryker from $425.00 to $435.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, Stryker currently has an average rating of "Moderate Buy" and a consensus price target of $427.30.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the completion of the sale, the director now directly owns 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 5.20% of the company's stock.

Stryker Trading Down 0.9%

Shares of Stryker stock traded down $3.53 on Wednesday, reaching $380.25. 1,158,176 shares of the company were exchanged, compared to its average volume of 1,344,556. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The firm has a market capitalization of $145.14 billion, a price-to-earnings ratio of 49.00, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The stock has a fifty day moving average price of $368.24 and a 200-day moving average price of $376.20.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, beating analysts' consensus estimates of $2.73 by $0.11. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The company had revenue of $5.87 billion during the quarter, compared to analyst estimates of $5.68 billion. During the same period in the prior year, the firm earned $2.50 earnings per share. The business's quarterly revenue was up 11.9% on a year-over-year basis. On average, analysts expect that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be given a dividend of $0.84 per share. The ex-dividend date is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. Stryker's payout ratio is presently 45.41%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.